Article
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.
Antimicrobial agents and chemotherapy - 1 Feb 2007
Grossman Trudy H, Bartels Douglas J, Mullin Steve, Gross Christian H, Parsons Jonathan D, Liao Yusheng, Grillot Anne-Laure, Stamos Dean, Olson Eric R, Charifson Paul S, Mani Nagraj
Abstract excerpt
A structure-guided drug design approach was used to optimize a novel series of aminobenzimidazoles that inhibit the essential ATPase activities of bacterial DNA gyrase and topoisomerase IV and that show potent activities against a variety of bacterial pathogens. Two such compounds, VRT-125853 and VRT-752586, were characterized for their target specificities and preferences in bacteria. In metabolite incorporation...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.